

RARE TUMOURS COMMITTEE
THURSDAY, OCTOBER 18, 2017, 12:00PM – 1:00PM
AMPHITHEATRE, KLINIKUM DER UNIVERSITÄT MÜNCHEN, DEPARTMENT OF GYNECOLOGY AND
OBSTETRICS, CAMPUS INNENSTADT, MAISTR. 11, MÜNCHEN
CHAIR: J. LEDERMANN CO-CHAIR: I RAY-COCQUARD (FOR C. SCOTT)
HARMONIZATION LIAISONS: FARRELLY (OPS), PAUL (STATS)



SUMMARY OF SLIDES/REPORT

CLOSED/PUBLISHED TRIALS:

[ALEINOR TRIAL](#); [TROPHIMMUN- PRESENTATION AT ESMO 2018](#)
[MEOC/GOG241- SUBMITTED FOR PUBLICATION](#)

ON-GOING CLINICAL TRIALS:

[EORTC HIGH GRADE UTERINE SARCOMA 55115/62113](#)
[NICC TRIAL \(CLEAR CELL\)](#)
[TROPHIMUN \(GTD\)](#)

UPDATE OF TRIALS IN DEVELOPMENT:

[LOW GRADE SEROUS OVARIAN CANCER](#) [KOHN](#)

DISCUSSION OF DESIGN AND RATIONALE OF ACCEPTING LETROZOLE IN BOTH ARMS. THIS IS A NON-INFERIORITY TRIAL OF TWO TREATMENTS, NEITHER OF WHICH ARE TRULY SOC. A DEMONSTRATION OF NON-INFERIORITY WOULD MEAN THAT CHEMOTHERAPY HAS NOTHING EXTRA TO ADD TO LETROZOLE. NO ALTERNATIVE DESIGNS WERE SUGGESTED. NON NCTN GROUPS WILL NEED TO DECIDE IF THEY WISH TO JOIN, AND SEEK LOCAL FUNDING. ALTERNATIVE DESIGNS MAY BE CONSIDERED BY OTHER CO-OP GROUPS BUT AT THE MOMENT, THIS IS THE ONLY TRIAL PROPOSAL

NEW/CONCEPTS PROPOSALS:

[IMMUNE THERAPY IN CLEAR CELL GYNECOLOGIC CANCERS \(ITICC\)](#).
[COMBINATION DURVALUMAB AND TREMELIMUMAB IN RECURRENT
CLEAR CELL OVARIAN CANCER](#) [HIRTE](#)

FUNDING ROUTE NOT YET CLEAR. DISCUSSION OF STATISTICS PENDING; MORE INFORMATION LIKELY TO BE AVAILABLE FOR SPRING 2019 MEETING

[MACCO: DURVALUMAB V INVESTIGATOR CHOICE IN RECURRENT](#) [HEONG](#)
[CLEAR CELL OVARIAN CANCER](#)

TWO CLEAR CELL STUDIES PROPOSED AS A GCIG INTERGROUP TRIALS. MACCO, SINGAPORE-LED ACADEMIC STUDY WITH FUNDING FROM AUSTRALIA (ANZGOG) SECURED

ATARI

BANERJEE

PHASE II PROOF-OF-CONCEPT STUDY OF ATR INHIBITOR (AZD6738) IN COMBINATION WITH OLAPARIB IN ARID1A MUT/ WT CLEAR CELL, AND OTHER GYNAE CANCERS.

SOME FUNDING FROM AZ SECURED; AWAITING UK FUNDING/ENDORSEMENT

ROSCAN- CARBOZATINIB IN UTERINE AND OVARIAN SARCOMA

RAY-COCQUARD

FUTURE DIRECTIONS:

GCIG-ESGO RARE TUMOUR GUIDELINE UPDATE PROJECT

RAY-COCQUARD/LEDERMANN

UPDATED GUIDELINES- DEVELOPMENT OF ALGORITHM IN CONJUNCTION WITH ESGO APP. FIRST 10 RARE TUMOURS TO BE COMPLETED BY ESGO/GCIG ATHENS 2019. 2 CO-ORDINATIONS AND UP TO 8 CO-WORKERS/REVIEWERS FROM GCIG GROUPS PER TUMOUR TYPE. APP DEVELOPMENT THROUGH ESGO